로딩 중...
52주 최고가 대비 57.9% 위치
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $128.3M | $200.5M | $154.0M | $160.0M |
| 영업이익 | - | $-304.8M | $-310.4M | $-290.7M | $-557.6M |
| 당기순이익 | - | $-314.2M | $-306.7M | $-309.9M | $-546.4M |
| 잉여현금흐름 (FCF) | - | $-280.1M | $-268.0M | $-212.2M | $-118.9M |
| 수익성 비율 | |||||
| 영업이익률 | - | -237.6% | -154.8% | -188.7% | -348.5% |
| 순이익률 | - | -244.9% | -153.0% | -201.2% | -341.5% |
| ROE (자기자본이익률) | - | -55.8% | -43.7% | -61.2% | -10214.5% |
| ROA (자산이익률) | - | -17.8% | -17.6% | -24.6% | -69.7% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 56.3% | -23.2% | 3.9% |
| EPS 성장률 (YoY) | - | - | 13.6% | -30.6% | -15.2% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | 6.1x | 2.9x | 0.9x | 131.2x |
| PSR (주가매출배수) | - | 26.8x | 10.1x | 3.1x | 4.4x |
| FCF Yield | - | -8.1% | -13.3% | -44.4% | -16.9% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 1.68 | 1.33 | 1.33 | 131.32 |
| 유동비율 | - | 3.24 | 7.81 | 7.48 | 5.15 |
MOLINA HEALTHCARE INC
$179.86
$9.4B